Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
Ceryx Medical appoints Chas Taylor as its Chairman.
FREMONT, CA: Chas Taylor joins as Chairman at Ceryx Medical, the business behind a revolutionary technology that could change the way patients with serious heart diseases are treated. Taylor brings with the experience in developing and leading medical device firms. These comprise three international cardiovascular businesses – MedNova, Novate and Veryan. Taylor founded each of these enterprises, raising over £100m in the capital during the process.
This appointment comes at a critical time for Ceryx Medical, preparing for its cardiac rhythm management device. The scientists behind the invention hold the key to increasing the heart’s efficiency and allowing it to repair itself.
Ceryx Medical’s technology is unique in its potential to alleviate the debilitating symptoms of heart failure while simultaneously offering the opportunity to repair itself. The firm spun-out of Bath and Bristol Universities and developed the technology in partnership with Auckland University in New Zealand. It has undergone rigorous laboratory testing and pre-clinical evaluations and is scheduled to be trialled in humans later this year.
Ceryx Medical’s technology has sparked interest from domestic and overseas markets and has drawn investment from some of the UK’s leading MedTech investors comprising ParkWalk, and the Development Bank of Wales. Chas Taylor's appointment is the latest in a series of moves to further develop momentum as the firm eyes up its markets. The appointment of Chas as Chairman of Ceryx Medical reflects just how impressive this company is and his belief in the revolutionary technology that the teams are building. The firm is delighted to welcome him to the team and look forward to working with him and the Board in preparing for this pivotal trial.
Ceryx Medical technology can enhance cardiac output and enhance cardiac repair in heart failure patients. Stuart and the team have done an exceptional job so far, and the company is delighted to be associated with this exciting project.
Read Also
